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Eltrombopag, low-dose rituximab, and dexamethasone combi-
nation as frontline treatment of newly diagnosed immune
thrombocytopaenia
Immune thrombocytopenia (ITP) results from a combination
of pathological antiplatelet antibodies, impaired megakary-
opoiesis and T cell-mediated platelet destruction. Frontline
treatment for newly diagnosed (ND) ITP includes prednisone,
intravenous immunoglobulin and anti-D (Lambert & Gern-
sheimer, 2017). High-dose dexamethasone (HDD) is effective
in ~85% of adults, but relapse will occur in ~60% (Wei et al,
2016). Low-dose rituximab (100 mg) has been used for ITP,
showing an activity similar to 375-mg/m2 doses. Sustained
response rates of 63–76% have been reported using rituximab
plus HDD as frontline therapy (Zaja et al, 2010; Gomez-
Almaguer et al, 2013). Eltrombopag stimulates throm-
bopoiesis, but also suppresses T-cell responses to platelet
auto-antigens and induces regulatory T cells (Tregs) (Bao
et al, 2010). We have used eltrombopag plus HDD as a feasi-
ble first-line therapy, albeit relapses occurred in 30% of
patients (Gomez-Almaguer et al, 2014). The lack of sustained
responses in adults with ITP has stimulated the search for
treatment that could modify the natural course of, and poten-
tially cure, the disease. Thus, we conducted a single centre
pilot study to assess the safety and efficacy of triple therapy,
including eltrombopag, low-dose rituximab and HDD. This
single arm, open-label, study included ND ITP patients from
Hospital Universitario ‘Dr. Jose Eleuterio Gonzalez’ in Mon-
terrey, Mexico (Clinical trials.gov NCT02834286). Eligible
patients were ≥16 years of age, without previous therapy, and
≤30 9 109/L platelets. Bleeding was scored according to the
International Working Group (Rodeghiero et al, 2013). Par-
ticipants were excluded if they had active infection (human
immunodeficiency virus, hepatitis), drug-associated thrombo-
cytopaenia, malignancy or were pregnant. Our ethics commit-
tee approved the study, which was performed in accordance
with the Declaration of Helsinski. Outpatient treatment con-
sisted of eltrombopag 50 mg/day for 28 days (1–28), oral dex-
amethasone 40 mg/day for 4 days (1–4), and low dose
rituximab 100 mg weekly for 4 weeks (days 1, 7, 14, and 21).
Eltrombopag was suspended if platelets were ≥ 400 9 109/l. A
complete blood count was performed at baseline, on days 3,
5 and 7, and then weekly for 28 days, monthly until month 6,
and every 3 months thereafter. Primary outcome was
response rate at the end of treatment (day 28). Response and
complete response (CR) were defined as an increase in platelet
counts ≥30 9 109/l and ≥100 9 109/l, respectively. Secondary
outcomes included 2-year relapse-free survival (RFS)
considered from the day of initial response until relapse
(<30 9 109/l platelets), duration of response (DOR) included
the period of time of any responses achieved (CR or response)
until relapse. Treatment side effects were assessed according
to the National Cancer Institute Common Terminology Crite-
ria for Adverse Events, v.40 (https://evs.nci.nih.gov/ftp1/
CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf).
The Kaplan-Meier method was used to calculate probability
of RFS; statistical analysis was performed with SPSS software
version 200 for Mac (IBM, Armonk, NY, USA).
Thirteen consecutive patients were enrolled; their charac-
teristics are reported in Table I. Median follow-up was
141 months (range 14–24). Median platelet count at diag-
nosis was 4 9 109/l (range 08–28). Median bleeding grade
was 2 (range 1–3). All patients responded and all but 1
achieved CR during treatment (92%). Median time to
response was 4 days (range 3–10) and to CR 9 days (7–22).
Five patients received an additional HDD course due to
declining platelet counts; two failed to achieve platelets
≥100 9 109/l at evaluation, thus CR rate at day 28 was
846% (response: 100%). Two patients achieved platelets
>400 9 109/l (days 14 and 21). One patient was lost to fol-
low-up 2 weeks after response evaluation. One patient lost
CR and received danazol for 5 months elsewhere, re-achiev-
ing CR and currently remains treatment-free. Two patients
relapsed 5 and 12 months after diagnosis; 2-year probability
of RFS was 79% (Fig 1). Currently, all but the relapsed
patients remain treatment-free in CR.
Median DOR was 11 months (range 05–23). Outpatient
treatment was well tolerated. One patient reported mild myal-
gia, 2 had insomnia, and one had fever related to rituximab.
Combination short-duration frontline therapy with the
rationale of achieving prolonged remissions has not been
attempted previously with these three agents. All patients
quickly responded and most reached CR, similarly to previ-
ous experience with eltrombopag and rituximab plus HDD
(Gomez-Almaguer et al, 2013, 2014). The present report can
attest to the efficacy of more aggressive therapy early in the
course of ITP as it led to an RFS of almost 80% at
12 months that was sustained, in contrast to 667% in our
previous report with eltrombopag plus HDD (Gomez-Alma-
guer et al, 2014). Our previous experience with rituximab
and HDD showed a similar RFS (84%) at 12 months
(Gomez-Almaguer et al, 2013). Interestingly 3 of the 5
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patients who received an additional dexamethasone bolus
either relapsed or did not achieve a stable CR, therefore bet-
ter initial responses may predict long-term remission, as pre-
viously suggested. (Gomez-Almaguer et al, 2013) Two other
studies also have included eltrombopag in ND patients, but
not as a frontline therapy; both suggested that the early addi-
tion of eltrombopag could be of value before ITP evolves to
persistent or chronic phases (Tripathi et al, 2014; Gonzalez-
Lopez et al, 2017). The capacity of eltrombopag and ritux-
imab for improving T cell subsets, particularly Tregs, may
help explain these observations (Bao et al, 2010). This strat-
egy could lead to cost-efficiency, with a total cost of US
$1400 in our institution, compared with that of continued
treatment and loss of work productivity, issues relevant in a
limited-resources context (Efficace et al, 2016).
Limitations of our study include a small sample size and
lack of a comparative, randomized design. Furthermore, this
therapy is not perfect; despite intense treatment some
patients lost CR and 2 relapsed, and while the actual long-
term DOR remains to be determined, we have achieved an
encouraging start, supporting our concept of early, and
potentially splenectomy-sparing, management. In summary,
we have found that this combination is a safe, highly effec-
tive, feasible and relatively durable alternative in ITP. Further
investigation is needed to establish if this early ‘total’ therapy
approach will enable most patients to achieve long-term CR
and treatment-free remission or will only delay relapse and
the inevitable onset of chronic ITP.
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Table I. Characteristics and outcomes of 13 adults with newly diagnosed immune thrombocytopenia treated with the frontline combination
rituximab, eltrombopag and high-dose dexamethasone.
Pt Sex/age (years)
Baseline platelet
count (9109/l) BR TTR (days) TTCR (days) R28
Relapse
(months) Current status
Follow-up
(months) TFR
1 M/21 11 CR 6 11 CR No CR 24 Yes
2 M/50 6 CR 7 14 CR* No CR 20 Yes
3 F/61 2 CR 3 7 CR No CR 175 Yes
4 F/54 5 CR 5 7 CR* No CR 197 Yes
5 F/16 28 CR 3 7 CR* Yes (14) CR 183 No
6 F/26 4 CR 5 22 CR No CR 105 Yes
7 M/57 12 CR 3 7 CR No CR‡ 141 Yes
8 F/40 12 R 4 – R* Yes (5) R 152 No
9 F/26 4 CR 4 7 CR No CR 12 Yes
10 F/42 13 CR 10 10 CR No Unknown 14† -
11 F/59 14 CR 10 17 CR No CR 93 Yes
12 M/19 45 CR 3 8 R* No R 52 Yes
13 M/27 08 CR 3 11 CR No CR 46 Yes
BR, best response; CR, complete response, defined as platelet count ≥100 9 109/l; F, female; M, male; Pt, patient; R, response. defined as platelet
count ≥30 9 109/l; R28, response at day 28; TFR, treatment-free remission; TTCR time to complete response; TTR time to response.
*Patients received a second four-day course of high dose dexamethasone due to declining platelet counts.
†Patient lost to follow-up.
‡Received danazol in another institution.
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Fig 1. Probability of relapse-free survival (RFS) in 13 patients with
newly diagnosed immune thrombocytopenia treated with a short
course of eltrombopag, low-dose rituximab, and high-dose dexam-
ethasone.
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Post-ABVD biopsy results, and not post-ABVD FDG-PET results,
predict outcome in early-stage Hodgkin lymphoma
We read with interest the recently published article by
Milgrom et al (2017) entitled ‘Early-stage Hodgkin lymphoma
outcomes after combined modality therapy according to the
post-chemotherapy 5-point score: can residual pet-positive dis-
ease be cured with radiotherapy alone?’. Their study included
174 patients with early-stage (I-II) Hodgkin lymphoma
treated with ABVD (doxorubicin, bleomycin, vincristine;
dacarbazine; median 4 cycles, range 2–6) followed by an
18F-fluoro-2-deoxy-D-glucose positron emission tomography
(FDG-PET) scan. Patients were treated with additional radia-
tion therapy (RT) regardless of FDG-PET findings. The prog-
nostic value of post-ABVD FDG-PET results according to the
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